Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia

Pharmacogenomics

Volumn 13, Issue 8, 2012, Pages 843-846

  Kuzman, Martina Rojnic ^a   Müller, Daniel J ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

antipsychotics; diabetes; dyslipidemia; hypertension; metabolic syndrome; methylenetetrahydrofolate reductase enzyme; MTHFR; pharmacogenetics; polymorphisms

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; INSULIN; METHIONINE; NEUROLEPTIC AGENT;

ABDOMINAL OBESITY; ALLELE; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; AMINO ACID SUBSTITUTION; CARDIOVASCULAR RISK; DYSLIPIDEMIA; EDITORIAL; ENZYME DEFICIENCY; GENE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HOMOCYSTEINE METABOLISM; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC DISORDER; MTHFR GENE; PHARMACOGENETICS; SCHIZOPHRENIA; SERUM HOMOCYSTEINE LEVEL;

ANTIPSYCHOTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; GENETIC ASSOCIATION STUDIES; HOMOCYSTEINE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84862022001     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.64     Document Type: Editorial

References (24)

1. De Hert M, Schreurs V, Vancampfort D, van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8(1), 15-22 (2009).
2. Casey DE, Haupt DW, Newcomer JW et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J. Clin. Psychiatry. 65(Suppl. 7), 4-18 (2004).
3. Lett TA, Wallace TJ, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol. Psychiatry 17(3), 242-266 (2012).
4. Refsum H, Smith AD, Ueland PM et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin. Chem. 50(1), 3-32 (2004).
5. Ellingrod VL, Miller DD, Taylor SF et al. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr. Res. 98(1-3), 47-54 (2008).
6. van Winkel R, Rutten BP, Peerbooms O, Peuskens J, van Os J, De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr. Res. 121(1-3), 193-198 (2010).
7. van Winkel R, Moons T, Peerbooms O et al. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. Int. Clin. Psychopharmacol. 25(5), 270-276 (2010).
8. Leclerc D, Sibani S, Rozen R. Molecular Biology of Methylenetetrahydrofolate Reductase (MTHFR) and Overview of Mutations/ Polymorphisms. Landes Bioscience, TX, USA.
9. Bellamy MF, McDowell IF. Putative mechanisms for vascular damage by homocysteine. J. Inherit. Metab. Dis. 20(2), 307-315 (1997)
10. Klerk M, Verhoef P, Clarke R et al. MTHFR 677CT polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288(16), 2023-2031 (2002).
11. Qian X, Lu Z, Tan M, Liu H, Lu D. A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur. J. Hum. Genet. 15(12), 1239-1245 (2007).
12. Yamada K, Chen ZT, Rozen R, Matthews RG. Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc. Natl Acad. Sci. USA 98(26), 14853-14858 (2001).
13. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. Nat. Rev. Genet. 8(4), 253-262 (2007).
14. Shi J, Gershon ES, Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr. Res. 104(1-3), 96-107 (2008).
15. Adkins DE, Aberg K, McClay JL et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol. Psychiatry 16(3), 321-332 (2011).
16. Terruzzi I, Senesi P, Fermo I, Lattuada G, Luzi L. Are genetic variants of the methyl group metabolism enzymes risk factors predisposing to obesity? J. Endocrinol. Invest. 30(9), 747-753 (2007).
17. Lewis SJ, Lawlor DA, Davey Smith G et al. The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. Mol. Psychiatry 11(4), 352-360 (2006).
18. Chen AR, Zhang HG, Wang ZP. C-reactive protein, vitamin B12 and C677T polymorphism of N-5,10- methylenetetrahydrofolate reductase gene are related to insulin resistance and risk factors for metabolic syndrome in Chinese population. Clin. Invest. Med. 33(5), E290-E297 (2010).
19. Loos RJF, Lindgren CM, Li S et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity Nat. Genet. 40(6), 768-775 (2008).
20. Zeggini E, Scott LJ, Saxena R et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 40(5), 638-645 (2008).
21. Eren E, Yeǧin A, Yilmaz N, Herken H. Serum total homocystein, folate and vitamin B12 levels and their correlation with antipsychotic drug doses in adult male patients with chronic schizophrenia. Clin. Lab. 56(11-12), 513-518 (2010).
22. Cheng LS, Prasad AN, Rieder MJ. Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents. Can. J. Clin. Pharmacol. 17(1), e5-e46 (2010).
23. PIMS PhyzioType™ System: psychotropic-induced metabolic symptoms. www.genomas.net/phyziotype-pims.php
24. Diabetes Trials Unit. www.dtu.ox.ac.uk